皮膚病治療市場：全球產業規模、市場佔有率、趨勢、機會和預測（按應用、藥物類別和地區分類）、競爭格局（2021-2031 年）

全球皮膚病治療市場預計將從 2025 年的 221.1 億美元成長到 2031 年的 368.4 億美元，複合年成長率為 8.88%。

該市場涵蓋多種藥物製劑、生物製藥和全身用藥，用於治療各種皮膚疾病，從慢性發炎性疾病到皮膚惡性腫瘤。市場擴張的主要促進因素包括：皮膚疾病盛行率不斷上升、全球人口老化導致老年人更容易患退化性疾病、診斷能力的提高以及公眾對皮膚健康的日益重視，所有這些因素共同加速了處方藥的使用。例如，預計到2025年，美國將新增約212,200例黑色素瘤病例，凸顯了對有效治療性介入的迫切需求。儘管成長勢頭強勁，但由於生物製藥和免疫調節劑價格高昂，該市場仍面臨嚴峻挑戰。嚴格的監管要求和藥物研發方面的大量資本投入往往導致高價策略，加重醫療預算負擔，並限制了價格敏感型新興市場患者獲得新療法的機會。

市場促進因素

受標靶特定免疫通路單株抗體商業性成功的推動，生物製藥和生物相似藥產業的快速擴張成為市場價值創造的主要驅動力。針對異位性皮膚炎和銀屑病等疾病的高效療法正獲得顯著的價格溢價，並透過取代傳統的系統性療法，推動了整體市場銷售的成長。這種向高價值免疫調節藥物的轉變在主要製藥公司的表現中得到了清晰的體現。例如，賽諾菲報告稱，其旗艦生物製藥產品Dupixent在2024年全年銷售額達到130.72億歐元，年增23.1%。同時，諾華的免疫學藥物Cosentyx在2024年全年銷售額達61億美元，以外匯計算成長25%。強大的臨床研發管線和頻繁的FDA產品核可，透過引入新的作用機制來應對以往難以治療的皮膚疾病，進一步加速了市場的動態。創新治療方法的持續監管核准刺激了研發資金的持續流入，同時也為臨床醫生提供了更廣泛的病患管理選擇。 2024年，FDA核准了七種新的皮膚病療法，並擴大了七種現有療法的適應症。這確保了競爭環境的形成，促進了價格多元化，並改善了全球不同患者群體獲得治療的機會。

市場挑戰

先進生物製藥和免疫調節藥物的高成本是限制全球皮膚病治療市場商業性擴張的主要阻礙因素。製藥開發商被迫投入巨額資金以應對嚴格的監管環境，並不得不採取高定價策略來收回這些投資。高昂的價格給公共和私人醫療保健預算帶來了沉重負擔，並導致嚴格的報銷政策，限制了臨床療效更佳藥物的市場滲透。這種經濟狀況實際上為新興經濟體中自付費用高的患者設定了進入門檻，阻礙了潛在市場潛力巨大的地區的市場滲透。考慮到大量患者由於經濟拮据而無法獲得足夠的醫療保健，這些定價挑戰的影響更為顯著。慢性皮膚病的普遍存在代表著巨大的潛在市場，但無法將這種需求貨幣化限制了整個產業的整體收入。例如，據估計，到2025年，全球將有超過1.25億人患有銀屑病。疾病負擔沉重，加上高品質治療資源有限，導致醫療系統優先考慮成本較低的學名藥，而不是創新但昂貴的治療方法，從而造成很大一部分市場價值未能實現。

市場趨勢

JAK抑制劑在自體免疫皮膚病治療中的應用日益廣泛，為白斑症和異位性皮膚炎等複雜疾病提供了強效的非生物製藥替代方案，從而改變了治療格局。與傳統的全身性用藥不同，這些小分子抑制劑擴大被開發為局部用藥，具有良好的安全性和標靶療效，介於皮質類固醇和單株抗體之間。這類療法正迅速進入市場，滿足了局部自體免疫反應領域巨大的未滿足需求，並有效取代了傳統治療方法。例如，Incyte公司報告稱，其局部JAK抑制劑Opzerula在2024年的全年淨銷售額為5.08億美元，年增50%，這主要得益於市場對特應性皮膚炎和白斑的強勁需求。同時，隨著患者和臨床醫生尋求更安全、更持久的皮質類固醇替代療法，新型非類固醇類局部療法的研發正在加速前進。這一趨勢的特點是引入了創新的作用機制，例如PDE4抑制劑和AhR促效劑，這些藥物具有強大的抗發炎作用，且不會像類固醇那樣導致皮膚萎縮。這些製劑能夠持續控制敏感部位（類固醇使用受限）的慢性皮疹和發炎復發，從而擴大了其目標市場。例如，Arcutis Biotherapeutics公司報告稱，其Zoryve非類固醇類產品系列2024年全年淨銷售額達到1.665億美元，年增471%。

目錄

第1章：引言

第2章 分析方法

第3章執行摘要

第4章：客戶心聲

第5章：全球皮膚科治療藥物市場展望

• 市場規模及預測
  • 以金額為準
• 市佔率及預測
  • 依用途分類（脫髮症、皰疹、銀屑病、酒糟、異位性皮膚炎、其他）
  • 藥物分類（抗感染藥物、皮質類固醇、抗青春痘藥物、鈣Calcineurin抑制劑、類視色素、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美皮膚病治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲皮膚病治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太皮膚病治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲皮膚科藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲皮膚科藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 企業合併（M&A）
• 產品發布
• 近期趨勢

第13章：全球皮膚病治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客購買力
• 替代品的威脅

第15章 競爭格局

• Abbvie Inc.
• Almirall SA
• Amgen Inc.
• Bausch Health Companies Inc.
• Galderma SA
• GlaxoSmithKline PLC
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Bristol-Myers Squibb Company

第16章 策略建議

第17章 關於TSCI與免責聲明

The Global Dermatological Therapeutics Market is projected to grow from USD 22.11 Billion in 2025 to USD 36.84 Billion by 2031, demonstrating an 8.88% CAGR. This market encompasses a diverse array of pharmaceutical formulations, biologics, and systemic agents used to manage and treat skin conditions ranging from chronic inflammatory diseases to cutaneous malignancies. Market expansion is fundamentally driven by the escalating prevalence of skin disorders, an aging global population increasingly susceptible to dermatological degeneration, improvements in diagnostic capabilities, and a heightened public emphasis on skin health, which collectively accelerate the adoption of prescription-based treatments. For example, an estimated 212,200 new cases of melanoma are expected in the United States in 2025, highlighting the urgent demand for effective therapeutic interventions. Despite these strong growth indicators, the market faces significant challenges due to the prohibitive costs associated with advanced biologic therapies and immunomodulators. Stringent regulatory requirements and high capital investment for drug development often lead to premium pricing strategies that strain healthcare budgets and restrict patient access to novel treatments in price-sensitive emerging economies.

Market Driver

The rapid expansion of the biologics and biosimilars segment, propelled by the commercial success of monoclonal antibodies targeting specific immune pathways, has become the primary engine of value generation within the market. High-efficacy treatments for conditions such as atopic dermatitis and psoriasis are commanding significant premiums, displacing older systemic therapies and thereby elevating overall market revenue. This shift towards high-value immunomodulators is evident in the financial performance of leading pharmaceutical players; for instance, Sanofi reported its flagship biologic Dupixent achieved €13,072 million in full-year sales for 2024, representing a 23.1% growth, while Novartis' immunology drug Cosentyx reached USD 6.1 billion in sales for the full year 2024, an increase of 25% in constant currency. A robust clinical pipeline and frequent FDA product approvals are further accelerating market dynamics by introducing novel mechanisms of action that address previously recalcitrant dermatological conditions. The continuous regulatory success of innovative therapies encourages sustained capital flow into research and development while providing clinicians with a significantly broader arsenal for patient management. The FDA approved 7 new dermatologic therapies and granted expanded indications for 7 existing treatments throughout 2024, ensuring a competitive landscape that fosters price diversification and improved accessibility for diverse patient populations globally.

Market Challenge

The prohibitive costs associated with advanced biologic therapies and immunomodulators constitute a primary restraint on the commercial expansion of the Global Dermatological Therapeutics Market. Pharmaceutical developers incur substantial capital expenditures to navigate stringent regulatory landscapes, compelling them to adopt premium pricing strategies to recoup their investments. These elevated price points place an immense burden on public and private healthcare budgets, leading to restrictive reimbursement policies that limit the commercial uptake of clinically superior drugs. This financial dynamic effectively creates a barrier to entry for patients in emerging economies where out-of-pocket expenditures remain high, thereby stalling market penetration in regions that otherwise offer significant volume potential. The impact of this pricing challenge is magnified when considering the vast patient population that remains underserved due to economic constraints. Although the prevalence of chronic skin conditions presents a substantial addressable market, the inability to monetize this demand restricts overall industry revenue. For instance, in 2025, more than 125 million people worldwide were estimated to be living with psoriatic disease. The disconnect between this high disease burden and the limited accessibility of premium treatments ensures that a significant portion of market value remains unrealized, as healthcare systems prioritize lower-cost generics over novel but expensive therapeutic interventions.

Market Trends

The broadening applications of JAK inhibitors for autoimmune skin conditions are reshaping the treatment landscape by offering potent, non-biologic alternatives for complex diseases like vitiligo and atopic dermatitis. Unlike traditional systemic agents, these small-molecule inhibitors are increasingly being formulated as topicals, providing targeted efficacy with a favorable safety profile that bridges the gap between corticosteroids and monoclonal antibodies. This therapeutic class has seen rapid commercial adoption as it addresses significant unmet needs in localized autoimmune responses, effectively displacing older lines of therapy. For example, Incyte Corporation reported that its topical JAK inhibitor Opzelura generated full-year net product revenues of USD 508 million in 2024, reflecting a 50% increase driven by high demand in both atopic dermatitis and vitiligo indications. Simultaneously, the shift toward novel non-steroidal topical treatment options is gaining momentum as patients and clinicians seek safer, long-term alternatives to chronic corticosteroid use. This trend is characterized by the introduction of innovative mechanisms, such as PDE4 inhibitors and AhR agonists, which deliver robust anti-inflammatory efficacy without the cutaneous atrophy risks associated with steroids. These formulations are expanding the addressable market by enabling continuous management of chronic plaques and inflammatory flares in sensitive anatomical areas where steroid application is restricted. Arcutis Biotherapeutics, for instance, saw net product revenues for its non-steroidal franchise Zoryve reach USD 166.5 million for the full year 2024, representing a 471% growth over the prior year.

Key Market Players

• Abbvie Inc.
• Almirall SA
• Amgen Inc.
• Bausch Health Companies Inc.
• Galderma SA
• GlaxoSmithKline PLC
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Bristol-Myers Squibb Company

Report Scope

In this report, the Global Dermatological Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermatological Therapeutics Market, By Application

• Alopecia
• Herpes
• Psoriasis
• Rosacea
• Atopic Dermatitis
• Others

Dermatological Therapeutics Market, By Drug Class

• Anti-infectives
• Corticosteroids
• Anti-acne
• Calcineurin Inhibitors
• Retinoids
• Others

Dermatological Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dermatological Therapeutics Market.

Available Customizations:

Global Dermatological Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dermatological Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Application (Alopecia, Herpes, Psoriasis, Rosacea, Atopic Dermatitis, Others)
  • 5.2.2. By Drug Class (Anti-infectives, Corticosteroids, Anti-acne, Calcineurin Inhibitors, Retinoids, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Dermatological Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Application
  • 6.2.2. By Drug Class
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dermatological Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Application
      • 6.3.1.2.2. By Drug Class
  • 6.3.2. Canada Dermatological Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Application
      • 6.3.2.2.2. By Drug Class
  • 6.3.3. Mexico Dermatological Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Application
      • 6.3.3.2.2. By Drug Class

7. Europe Dermatological Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Application
  • 7.2.2. By Drug Class
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dermatological Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Application
      • 7.3.1.2.2. By Drug Class
  • 7.3.2. France Dermatological Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Application
      • 7.3.2.2.2. By Drug Class
  • 7.3.3. United Kingdom Dermatological Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Application
      • 7.3.3.2.2. By Drug Class
  • 7.3.4. Italy Dermatological Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Application
      • 7.3.4.2.2. By Drug Class
  • 7.3.5. Spain Dermatological Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Application
      • 7.3.5.2.2. By Drug Class

8. Asia Pacific Dermatological Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Application
  • 8.2.2. By Drug Class
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dermatological Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Application
      • 8.3.1.2.2. By Drug Class
  • 8.3.2. India Dermatological Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Application
      • 8.3.2.2.2. By Drug Class
  • 8.3.3. Japan Dermatological Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Application
      • 8.3.3.2.2. By Drug Class
  • 8.3.4. South Korea Dermatological Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Application
      • 8.3.4.2.2. By Drug Class
  • 8.3.5. Australia Dermatological Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Application
      • 8.3.5.2.2. By Drug Class

9. Middle East & Africa Dermatological Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Application
  • 9.2.2. By Drug Class
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Dermatological Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Application
      • 9.3.1.2.2. By Drug Class
  • 9.3.2. UAE Dermatological Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Application
      • 9.3.2.2.2. By Drug Class
  • 9.3.3. South Africa Dermatological Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Application
      • 9.3.3.2.2. By Drug Class

10. South America Dermatological Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Application
  • 10.2.2. By Drug Class
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dermatological Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Application
      • 10.3.1.2.2. By Drug Class
  • 10.3.2. Colombia Dermatological Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Application
      • 10.3.2.2.2. By Drug Class
  • 10.3.3. Argentina Dermatological Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Application
      • 10.3.3.2.2. By Drug Class

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Dermatological Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbvie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Almirall SA
• 15.3. Amgen Inc.
• 15.4. Bausch Health Companies Inc.
• 15.5. Galderma SA
• 15.6. GlaxoSmithKline PLC
• 15.7. Johnson & Johnson
• 15.8. Novartis AG
• 15.9. Pfizer Inc.
• 15.10. Bristol-Myers Squibb Company

16. Strategic Recommendations

17. About Us & Disclaimer